Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., and Generics (U.K.) Ltd. in a hearing before the Opposition Division of the European Patent Office (EPO). The three-member panel of the Opposition Division rejected all grounds of opposition, thus upholding the patent as grant.

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

Incyte

Pfizer

Investing in biopharmaceutical stocks is a lesson in quantity and quality. That is, the best pharma stocks have products that are commercially available.

3 Pharma Stocks Could Be the Pills Your Portfolio Needs

American Airlines

EnerSys

NRG Energy

Here are four stocks, EXEL, ENS, NRG and AAL, which meet the winning criteria.

4 Lucrative PEG-Based Value Stocks to Buy Now

Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress

Exelixis Inc. is a biotech company focused on oncology, with its main products being Cometriq and Cabometyx, which are used for treating thyroid and kidney cancer. The company faces a legal battle against MSN Laboratories over Cabometyx's patents, which could impact its profitability and intellectual property value. The final ruling on the patent infringement is expected in March or April 2024, with potential positive outcomes that could drive the stock's value.

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Full rights returned following Exelixis' corporate restructuring announced January 07, 2024 Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics LUND, SWEDEN / ACCESSWIRE / January 12, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that its early discovery partner Exelixis, Inc. has provided a notice of termination for the option and license agreement for novel antibodies for use in immuno-oncology therapeutics. It follows a recently announced corporate restructuring program within Exelixis, prioritizing its pipeline of clinical and near-clinical programs.

BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

Regeneron Pharmaceuticals

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2023, provided financial guidance for fiscal year 2024 and delivered an update on its business. Exelixis expects 2024 to be a year of pipeline progress as it advances its portfolio of promising biotherapeutics and small molecule candidates recently highlighted at its 2023 R&D Day and pursues potential near-term label expansion opportunities for CABO.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT / 7:30 p.m. ET. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location.

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

Alnylam Pharmaceuticals

argenx

Blueprint Medicines

Genmab - ADR

Seagen

Sarepta Therapeutics

Alexion Pharma

Celgene

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

5 Biotech Acquisition Targets To Accumulate In 2024

Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company's growing research and development pipeline, highlight recent clinical updates and elaborate on the company's continued efforts to serve more patients with cancer and generate sustaina.

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). “We are excited to progress zanzalintinib, our next-generation multi-targeted tyrosine kinase inhibitor, into this population of patients who oth.

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Arcus Biosciences

ALAMEDA, Calif. and HAYWARD, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). Exelixis i.

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 at 11:00 am ET / 8:00 am PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any.

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC). STELLAR-001 is a phase 1b trial evaluating zanzalintinib alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The findings are being presented today at 2:35 p.m. CST during the Oral Abstracts sess.

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

BioMarin Pharmaceutical

Halozyme Therapeutics

In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow's Cures

ACADIA Pharma

CRISPR Therapeutics

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.

3 Biotech Stocks With the Strongest Clinical Pipelines

Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and indirectly help our well-being.

3 Promising Biotech Stocks Flying Under the Radar

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.

News for Exelixis Stock (EXEL)